Innate Pharma to hold its Annual General Meeting of Shareholders on June 29, 2011, in Marseilles, France
Appointment of Catherine Moukheibir to the Executive board of Innate Pharma
Innate Pharma announces its turnover for the first quarter of 2011 and updates on its cash position
Innate Pharma and Transgene Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services
Innate Pharma announces the release of its Reference Document (in French)
Innate Pharma updates on its next meetings with analysts and investors
Innate Pharma reports 2010 financial results and updates on its drug candidates
Innate Pharma receives a milestone payment for IPH2201, a monoclonal antibody licensed to Novo Nordisk A/S
Innate Pharma SA reports annual operating revenue of 4.3 million euros for 2010
The US National Cancer Institute starts a Phase II clinical trial with Innate Pharma's IPH2101
